Yeh— finally a little momentum behind stock price——Oppenheimer analyst——“we believe Twirla's growing momentum among patients and providers will translate into robust sales growth in 2022+," Gershell opined.
"We expect contraceptive patch Twirla to address unsatisfied demand within the ~$4.1B US contraceptive market and to achieve 2025E sales of $260M. We encourage investors to build a position at current levels," the analyst summed up.
To this end, Gershell rates AGRX an Outperform (i.e. Buy), and his $4 price target suggests a robust upside of ~569%.
Turning now to the rest of the Street, 4 Buys and no Holds or Sells have been published in the last three months. Therefore, AGRX has a Strong Buy consensus rating. At $2.83, the average price target implies ~373% upside potential.
M
Does anyone know what has triggered the sudden increase in the stock trading volume today?
R
OLD news on share increase meeting. Why people selling today--Oppenhaur report good and no insider or institution selling at all.
m
I have held this stock before - I think it will be $2 in a month hang tight
t
With shares changing hands for $0.59 apiece, Oppenheimer analyst Leland Gershell sees an attractive entry point for investors.
“Recent telehealth partnership activation as well as DTC campaign rollout, consisting of several online strategies targeting key user segment, should strengthen business in 4Q and beyond. Preferred drug formulary placement on California's Medicaid program (serves ~15M) notable as ~one-third of contraceptive patch market is supplied through Medicaid. While AGRX's first few commercial quarters have been slow to hit their stride, we believe Twirla's growing momentum among patients and providers will translate into robust sales growth in 2022+," Gershell opined.
"We expect contraceptive patch Twirla to address unsatisfied demand within the ~$4.1B US contraceptive market and to achieve 2025E sales of $260M. We encourage investors to build a position at current levels," the analyst summed up.
To this end, Gershell rates AGRX an Outperform (i.e. Buy), and his $4 price target suggests a robust upside of ~569%.
Turning now to the rest of the Street, 4 Buys and no Holds or Sells have been published in the last three months. Therefore, AGRX has a Strong Buy consensus rating. At $2.83, the average price target implies ~373% upside potential.
R
So now that they have the NASDAQ non compliance letter——does this prompt them to do some dramatic footwork and advertising ideas to quickly boost the stock price above the $1 minimum? Or do they finally sell? Or do they do nothing and just watch it fail? Should be interesting— I’ve still got some invested, so I’ll hang in for the ride and see.
M
We all knew the delisting notice was coming. How about rallying behind the company, if you believe in it, buy more shares and get the share price above $1. The Reddit Army can seem to do it quite easily.
t
Shorts have been going up and there is an ongoing attack. Some of these will close out before the end of the year. The company has until May to get back to $1. Surely, this will go back to $1 by then... Seriously the next quarterly report is going to have an increase in earnings with Cali-Medicaid coming on line... Well at least one would think so.
K
So by my count, the delisting notice should come today or tomorrow.
t
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 9, 2021, Agile Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”).
The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until May 9, 2022 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide the Company written confirmation of compliance with the Bid Price Requirement.
If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second 180 calendar day compliance period, by effecting a reverse stock split, if necessary.
If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Hearings Panel. There can be no assurance that the Company will regain compliance or otherwise maintain compliance with any of the other listing requirements.
The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement.
t
If you see the potential of women's health as an industry, check out DARE. They have a very important decision coming up in early December that has the potential to be big. They are partnered with Bayer, supported by the Gates foundation and other large investors and their CEO has done a great job of protecting shareholder value. Do some DD and see if you think there is something you like. I have a small amount invested, but the risk/reward looks like a good opportunity.
J
Can they just sell this company already?? they'll never compete with the big boys in this space even with a superior product. Just sell it already!!! Give us a break and stop being so dogmatic. You have no chance at making it solo. SELL!!!!!!!
t
This quarterly report represents an earnings surprise of 5.26%. A quarter ago, it was expected that this developer of prescription contraceptive products for women would post a loss of $0.21 per share when it actually produced a loss of $0.20, delivering a surprise of 4.76%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
W
Just looked at sales per Onslaught on stocktwits. They have to increase their marketing by ~4X to get into the $80M sales range. I'm guessing that will be at or above break even for AGRX (no facts--just raw guess).
R
TWIRLA sales figures--link is below--a straight diagonal line heading upwards all the way- Do you really want sell now. Granted in hind sight I should have sold when it was $4.50 a share, but I didn't--that doesn't mean I should sell today and just give my shares away when they can easily double or triple. Damage is done. Downside is minimal at this point, so why sell.
Man this thing is slow bleeding to zero day by day! Red every single day!
W
From all I can understand, Twirla is a "better mousetrap" and sales are increasing well. IMHO an important part of the picture is that most of the new sales continue with follow-on buying which indicates satisfaction with the product. TBD if a "tipping point" is reached where new sales grow rapidly from customers switching to Twirla from other products.
R
Get in to this stock now at these much lower prices than it should be—Perceptive bought 5 million dollars worth of stock!!---This is great news! This group already had 21 million invested and they are not going to throw good money after bad. This is a major player that has a lot to loose if they are wrong, and a lot to gain if they are right! I'll go along with them!
R
TWIRLA sales figures---a straight diagonal line heading upwards all the way--stock price should be over a dollar right now.
"We expect contraceptive patch Twirla to address unsatisfied demand within the ~$4.1B US contraceptive market and to achieve 2025E sales of $260M. We encourage investors to build a position at current levels," the analyst summed up.
To this end, Gershell rates AGRX an Outperform (i.e. Buy), and his $4 price target suggests a robust upside of ~569%.
Turning now to the rest of the Street, 4 Buys and no Holds or Sells have been published in the last three months. Therefore, AGRX has a Strong Buy consensus rating. At $2.83, the average price target implies ~373% upside potential.
hang tight
“Recent telehealth partnership activation as well as DTC campaign rollout, consisting of several online strategies targeting key user segment, should strengthen business in 4Q and beyond. Preferred drug formulary placement on California's Medicaid program (serves ~15M) notable as ~one-third of contraceptive patch market is supplied through Medicaid. While AGRX's first few commercial quarters have been slow to hit their stride, we believe Twirla's growing momentum among patients and providers will translate into robust sales growth in 2022+," Gershell opined.
"We expect contraceptive patch Twirla to address unsatisfied demand within the ~$4.1B US contraceptive market and to achieve 2025E sales of $260M. We encourage investors to build a position at current levels," the analyst summed up.
To this end, Gershell rates AGRX an Outperform (i.e. Buy), and his $4 price target suggests a robust upside of ~569%.
Turning now to the rest of the Street, 4 Buys and no Holds or Sells have been published in the last three months. Therefore, AGRX has a Strong Buy consensus rating. At $2.83, the average price target implies ~373% upside potential.
On November 9, 2021, Agile Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”).
The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until May 9, 2022 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide the Company written confirmation of compliance with the Bid Price Requirement.
If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second 180 calendar day compliance period, by effecting a reverse stock split, if necessary.
If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Hearings Panel. There can be no assurance that the Company will regain compliance or otherwise maintain compliance with any of the other listing requirements.
The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
https://charts.stocktwits.com/production/original_394212303.png
https://finance.yahoo.com/calendar/earnings?from=2021-10-31&to=2021-11-06&day=2021-11-02
https://charts.stocktwits.com/production/original_394212303.png